drugset / Trial / NCT06279364
A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
The aim of the study is to evaluate the efficacy and safety of SKB264 as first-line treatment for patients with unresectable recurrent or metastatic triple-negative breast cancer (TNBC) whose tumors do not express programmed cell death ligand 1 (PD-L1) or in patients with PD-L1 positive tumors who received prior anti-programmed cell death 1 (PD-1)/PD-L1 inhibitor in early setting
Timeline
- Start
- 2024-02-28
- Primary completion
- 2026-07
- Completion
- 2026-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Capecitabine | Small molecule | — | Oral |
| Comparator | Carboplatin | Small molecule | — | Intravenous |
| Comparator | Eribulin | Small molecule | — | Intravenous |
| Comparator | Paclitaxel | Small molecule | — | Intravenous |
| Subject | Sacituzumab Tirumotecan | Other / unclassified | — | Intravenous |